Founded in 2013, Tissium is a fast-moving medical device company dedicated to developing innovative tissue reconstruction solutions.
The company leverages its technology platforms to develop new innovative solutions in surgery for a positive impact on patients' lives. The company is headquartered in Paris, with a production facility in Roncq (near Lille) and an office in Boston.
Tissium's technology is based on research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital), who co-founded the company.
Tissium is developing surgical polymers for tissue repair during surgical procedures based on its proprietary, elastomeric, biodegradable, biocompatible polymers for in situ wound closure, in the presence of blood during surgery and tissue reconstruction.
The company's strategy is to develop a platform of innovations in the field of tissue reconstruction based on surgical polymers. These innovative devices, inspired by nature, will allow for less invasive surgery for the patient in areas such as Cardiovascular, Peripheral Nerve, Hernia and Digestive Surgery.
Tissium's mission is to bring a new era of body repair.
Tissium teams are driven by the conviction that their ability to innovate, their resilience and their ability to work as a team are fundamental to developing solutions that benefit patients' lives.
Joining Tissium means participating in a human adventure, in a stimulating and fast-growing environment, while helping to build a future leader in its field.
The team is composed of more than 13 different nationalities. Diversity is a strength at Tissium.
Tissium is part of the French Tech 120 startups for the second time in a row.
The offices are located in an emblematic building in the Bastille district.
The possibility of working from anywhere.
Transparency is one of their values, information is shared during regular staff meetings where all questions are welcome.